What is Alpha1-Proteinase Inhibitor?

Alpha1-Proteinase Inhibitor is a medication used to treat Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder that can lead to lung and liver diseases.

How big is the Alpha1-Proteinase Inhibitor Market?

The global Alpha1-Proteinase Inhibitor Market size was estimated at USD 1.6 Billion in 2023 and is expected to reach USD 4.8 Billion in 2033.

What is the Alpha1-Proteinase Inhibitor Market growth?

The global Alpha1-Proteinase Inhibitor Market is expected to grow at a compound annual growth rate of 11.5%. From 2024 To 2033

Who are the key companies/players in the Alpha1-Proteinase Inhibitor Market?

Some of the key players in the Alpha1-Proteinase Inhibitor Markets are Baxter International Inc., Sanofi , CSL Behring, Grifols S.A., Abenoea, Talecris Biotherapeutics Inc., PlasmaGen BioSciences Pvt. Ltd., Kamada Pharmaceuticals

What are the main end-use segments for Alpha1-Proteinase Inhibitors?

The main end-use segments are hospitals, specialty clinics, research institutes, and others, with hospitals holding 48% of the market share in 2023.

What are the recent product launches in this market?

Recent product launches include Sanofi's new Alpha1-Proteinase Inhibitor formulation in May 2023 and Abenoea's novel product in January 2023.

How are mergers impacting the market?

Mergers, such as those by CSL Behring (June 2023) and Talecris Biotherapeutics Inc. (February 2023), are enhancing research capabilities and expanding treatment options for AATD.

Alpha1-Proteinase hibitor Market Size, Share,

Global Alpha1-Proteinase Inhibitor Market By Dosage Form (Solid, Liquid) By Dose Amount ( 0.5 g, 1 g) By End-Use (Hospitals , Specialty Clinics, Research Institutes, Others, By End-Use) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

- Get a FREE Sample -

Our Clients